Year: 2021

Lithuanian electricity transmission operator LITGRID AB (company code 302564383, registered office address Karlo Emilio Gustavo Manerheimo st. 8, Vilnius, Lithuania), informs that on 16th December 2021 the opinion of the Audit Committee of the holding company UAB “EPSO-G” was received on the planned transactions with the related party AB “Ignitis gamyba”: – Tertiary active power reserve purchase and sale agreement (hereinafter referred to as the “Tertiary Reserve Agreement”);  – Isolated electricity system work service purchase and sale agreement (hereinafter referred to as the “Isolated Operation Service Agreement”) (hereinafter all together to as the “Transactions with related party”). On 16th December 2021, the Audit Committee of UAB “EPSO-G” considered the Transactions with related party and adopted the following decisions...

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced its inclusion on the NASDAQ Biotechnology Index (Nasdaq: NBI), effective on December 20, 2021. The NASDAQ Biotechnology Index tracks the performance of a set of biotechnology and pharmaceutical companies, classified by the Industry Classification Benchmark (ICB), currently listed on the NASDAQ stock exchange. Securities in this index must meet eligibility criteria including being listed on the NASDAQ Global Select Market or the NASDAQ Global Market. Securities must also meet market capitalization standards and maintain a minimum average daily trading volume...

New products leverage growing customer engagement for digital banking services MIDDLEFIELD, Ohio, Dec. 17, 2021 (GLOBE NEWSWIRE) — Middlefield Banc Corp. (NASDAQ: MBCN) announced the expansion of its digital banking capabilities to support growing customer engagement across digital channels. “Over the past two years, Middlefield Bank has experienced significant growth for our digital banking services. We continue to focus on creating a frictionless environment for our customers regardless of how they choose to interact with us,” stated Thomas Caldwell, Middlefield President and CEO. “As customer expectations evolve, our team continues to transform our digital capabilities and grow partnerships to serve our retail and business customers. Our commitment to service, quality and our communities are always at the forefront, and we are...

PEARL RIVER, N.Y., Dec. 17, 2021 (GLOBE NEWSWIRE) — Sterling Bancorp (NYSE: STL) today announced it has made a strategic investment in Goalsetter, an innovative mobile banking company aimed at promoting financial literacy and empowerment amongst K-12 students. According to studies compiled by the U.S. Financial Literacy and Education Commission, only one third of adults can answer at least four of five financial literacy questions on fundamental concepts such as mortgages, interest rates, inflation and risk. Goalsetter proactively addresses these knowledge gaps through educational resources, budgeting tips, and planning tools that promote financial literacy and learning, while augmenting the experience with an FDIC insured deposit product and online and in-store spending through its Cashola™ debit card. This investment marks an...

TEMPE, Ariz., Dec. 17, 2021 (GLOBE NEWSWIRE) — VirTra, Inc. (NASDAQ: VTSI), a global provider of judgmental use of force training simulators, and firearms training simulators for the law enforcement and military markets, has received a standing offer from the Government of Canada to supply marksmanship and judgmental use of force simulation technology to various law enforcement, border protection and corrections facilities throughout Canada. The standing offer allows the Government of Canada to repeatedly purchase goods and/or services, or a combination of goods and services at prearranged prices from VirTra, under set terms and conditions, when required. The award is part of a countrywide effort to enhance and standardize training from the Royal Canadian Mounted Police down to each individual agency. The award could include the...

IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in recurrent GBM anticipated in Q1 2022 Early collaboration with GCAR could support potential registrational path in GBM ERAS-801 is a highly CNS-penetrant EGFR inhibitor with broad activity against oncogenic EGFR variants SAN DIEGO, Dec. 17, 2021 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ERAS-801, an orally available small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central...